HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

triflusal

inhibits platelet aggregation similarly to aspirin; structure
Also Known As:
2-acetoxy-4-trifluoromethylbenzoic acid; Disgren; Hormona brand of triflusal; Uriach brand of triflusal; 2- (acetyloxy)-4-(trifluoromethyl)benzoic acid
Networked: 73 relevant articles (8 outcomes, 22 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Alvarez-Sabín, José: 3 articles (01/2014 - 04/2003)
2. Cechetto, David F: 3 articles (12/2010 - 08/2005)
3. Cheng, Guanliang: 3 articles (12/2010 - 08/2005)
4. Whitehead, Shawn N: 2 articles (12/2010 - 02/2007)
5. Hachinski, Vladimir C: 2 articles (12/2010 - 02/2007)
6. Boey, Freddy Y C: 2 articles (05/2010 - 10/2009)
7. Umashankar, P R: 2 articles (05/2010 - 10/2009)
8. Arumugam, Sabareeswaran: 2 articles (05/2010 - 10/2009)
9. Mohanty, Mira: 2 articles (05/2010 - 10/2009)
10. Huang, Yingying: 2 articles (05/2010 - 10/2009)

Related Diseases

1. Stroke (Strokes)
2. Atrial Fibrillation
3. Body Weight (Weight, Body)
06/01/1990 - "The study of the prevention of platelet thrombi formation on these materials was carried out in 6 groups of 8 animals: group 1 (control), group 2 (5 mg/kg body weight/day acetylsalicylic acid), group 3 (20 mg/kg body weight/day acetylsalicylic acid), group 4 (15 mg/kg body wt/day triflusal plus 5 mg/kg body wt/day dipyridamole), group 5 (15 mg/kg body wt/day triflusal) and group 6 (5 mg/kg body wt/day acetylsalicylic acid plus 5 mg/kg body wt/day dipyridamole). "
10/01/1989 - "Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: group I, control; group II, 5 mg/kg body weight/day acetylsalicylic acid; group III, 20 mg/kg body weight/day acetylsalicylic acid; group IV, 15 mg/kg body weight/day triflusal + 5 mg/kg body weight/day dipyridamole; group V, 15 mg/kg body weight/day triflusal; and group VI, 5 mg/kg body weight/day acetylsalicylic acid + 5 mg/kg body weight/day dipyridamole. "
05/01/1989 - "Groups of 7 mongrel dogs received treatment for 7 days prior to the trial: Group I, control; Group II, 5 mg/kg body weight/day acetylsalicylic acid; Group III, 20 mg/kg body wt/day acetylsalicylic acid; Group IV, 15 mg/kg body wt/day triflusal + 5 mg/kg body wt/day dipyridamole; Group V, 15 mg/kg body wt/day triflusal; and Group VI, 5 mg/kg body wt/day acetylsalicylic acid + 5 mg/kg body wt/day dipyridamole. "
11/01/2009 - "First, we prospectively tested platelet function with a rapid platelet function analyzer (VerifyNow-Aspirin) in patients with stable angina (male, age, 61.6 +/- 8.3, body weight, 69.3 +/- 11.2 kg) who maintained dual (aspirin 100 mg and clopidogrel 75 mg per day, n = 23) or triple (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day, n = 23) therapy for more than one month. "
04/01/2006 - "Assessment of the effects of triflusal in pressure overload-induced cardiac hypertrophy by aortic banding resulted in a significant reduction in the ratio of heart weight to body weight and in a reduction of the mRNA levels of the cardiac hypertrophy markers ANF and alpha-actinin compared with untreated banded rats. "
4. Cerebral Infarction
04/01/2003 - "Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial."
01/01/2006 - "Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation."
04/13/2004 - "Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study."
04/01/2003 - "We performed a randomized, double-blind, multicenter study to test the efficacy of triflusal (600 mg/d) versus aspirin (325 mg/d) for prevention of vascular events in patients with stroke or transient ischemic attack (Triflusal versus Aspirin in Cerebral Infarction Prevention [TACIP]). "
09/01/2005 - "The results of the following studies are reviewed and compared: the Swedish Aspirin Low-Dose Trial (SALT), the United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial, Dutch Transient Ischemic Attack (Dutch TIA) study (aspirin), the Canadian American Ticlopidine Study (CATS), the Ticlopidine Aspirin Stroke Study (TASS), the African American Antiplatelet Stroke Prevention Study (AAASPS) (ticlopidine), the Clopidogrel versus Aspirin in Patients at Risk of Recurrent Ischemic Events (CAPRIE) trial, the Management of Atherothrombosis With Clopidogrel in High-Risk Patients study (MATCH) (clopidogrel), the second European Stroke Prevention Study (ESPS2) (aspirin plus ER-DP), and the Triflusal versus Aspirin in Cerebral Infarction Prevention (TACIP) study. "
5. Transient Ischemic Attack

Related Drugs and Biologics

1. Aspirin (Acetylsalicylic Acid)
2. Dipyridamole (Persantine)
3. clopidogrel (Plavix)
4. Ticlopidine (Ticlid)
5. 4-trifluoromethylsalicylic acid (HTB)
6. indobufen
7. Anticoagulants
8. Cyclooxygenase 2 (Cyclooxygenase-2)
9. Messenger RNA (mRNA)
10. Epoprostenol (Prostacyclin)

Related Therapies and Procedures

1. Bioprosthesis
2. Stents
3. Drug-Eluting Stents
4. Transplants (Transplant)
5. Injections